Skip to main content
Treatment Resistant DepressionGeneticsCognitive functionDeviceDrug

What this study is

The purpose of this study is to examine the effects of interventional/procedural therapies for treatment-resistant depression (TRD) and Obsessive-Compulsive Disorder (OCD). These treatments include electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), racemic ketamine infusion and intranasal esketamine insufflation. The investigators will obtain various indicators, or biomarkers, of a depressed individuals' state before, during, and/or after these treatments. Such biomarkers include neurobehavioral testing, neuroimaging, electroencephalography, cognitive testing, vocal recordings, epi/genetic testing, and autonomic nervous system measures (i.e. "fight-or-flight" response). The results obtained from this study may provide novel antidepressant treatment response biomarkers, with the future goal of targeting a given treatment to an individual patient ("personalized medicine").

What's being tested

  • Electroconvulsive Therapy (ECT)

    Intervention · DEVICE

    ECT for the treatment of treatment-resistant depression OR Bipolar Disorder in an active major depressive episode

  • Transcranial Magnetic Stimulation (TMS)

    Intervention · DEVICE

    TMS for the treatment of treatment-resistant depression in an active major depressive episode

  • Ketamine

    Intervention · DRUG

    Intravenous ketamine infusion for the treatment of treatment-resistant depression in an active major depressive episode

  • Esketamine

    Intervention · DRUG

    Intranasal esketamine insufflation for the treatment of treatment-resistant depression in an active major depressive episode

  • Deep Transcranial Magnetic Stimulation (dTMS)

    Intervention · DEVICE

    TMS for the treatment of OCD

Study details

Sponsor
Mark Niciu
Conditions
Treatment Resistant Depression · Major Depressive Episode · Major Depression · Major Depressive Disorder · Bipolar Disorder · Bipolar Depression · Obsessive-Compulsive Disorder
Enrolling
1,000 people
Starts
2020-11-02
Est. completion
2050-08
Record
View on ClinicalTrials.gov ↗